SciBac

SciBac Creates Revolutionary Living Biotherapeutics to Treat Antibiotic-Resistant Diseases While Strengthening the Microbiome. We leverage novel platform technologies to enhance beneficial microorganisms, enabling the rapid, natural, and safe transfer of useful genetic traits. The resulting microbes possess all the best characteristics to target specific diseases through multiple modes of action while enhancing the microbiome for faster recovery and reduced risk of reinfection. By focusing on developing treatments for antibiotic-resistant diseases, SciBac addresses a rapidly growing medical need.SciBac’s first product targets *Clostridioides difficile* infection, the largest antibiotic-resistant threat in the U.S. Our microbes combat *C. difficile* by halting colonization, neutralizing toxins, and directly killing the bacteria. Unlike antibiotics, our product specifically targets *C. difficile*, allowing the rest of the patient’s microbiota to thrive, accelerating recovery, and reducing the risk of recurrence.